Furthermore, incidences associated with canakinumab peaked in 2017, with its reports constituting the majority (58%) of IL-1 inhibitor-related reports, reflecting its growing clinical applications, notably its 2017 approval for inflammation management in atherosclerotic cardiovascular disease (ASCVD) patients [1]. The gene discussed is IL1A; the disease is atherosclerosis.